HCC Archives - Page 3 of 5

Dr. Huichuan Sun: Focusing on the Asia-Pacific Region, Leading the Frontier – Exploring Breakthroughs in the Treatment of Hepatobiliary Tumor

By Peter W. PENG 2024.01.17

The 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023) recently concluded in Seoul, South Korea, bringing together top experts in liver and biliary system tumors from around the world to discuss clinical hot topics and challenges. Dr. Huichuan Sun from Zhongshan Hospital, Fudan University, China, shares and interprets the latest developments and frontiers, including the Asia-Pacific consensus and groundbreaking research with us.

Dr. Xinwei Wang: The Molecular Landscape and Clinical Significance of Liver Cancer

By Mourabit Halima 2024.01.17

Liver cancer is one of the most prevalent and deadliest cancers in China. Due to the low early diagnosis rate of liver cancer in clinical practice, treatment options such as radical liver resection and transplantation face significant limitations. In recent years, there has been a surge in liver cancer genomics research, providing new insights into early diagnosis, patient stratification, and treatment prognosis. From July 6th to 8th, 2023, the 13th Asia-Pacific Primary Liver Cancer Expert Conference (APPLE 2023) was held in Seoul, South Korea. During the conference, Dr. Xinwei Wang from the U.S. National Cancer Institute gave a special lecture on "The Molecular Landscape and Clinical Significance of Liver Cancer." Hepatology Digest had the privilege of inviting Dr. Wang to share recent significant developments in this research field and delve into the potential applications and prospects of liver cancer genomics research for early diagnosis and prognosis prediction.

Focusing on Hepatitis B, New Developments in the “Oasis” Project and Exploration of TAF’s Immune Modulation Effects

By Mourabit Halima 2023.12.22

The annual highlight in the field of hepatology, the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, is currently taking place in Boston, USA. Two research achievements related to the treatment and management of hepatitis B by Dr. Wenhong Zhang and Dr. Jiming Zhang 's team from Huashan Hospital, affiliated with Fudan University, have been included in the conference. One is a phase analysis of the Oasis Project, a study aimed at reducing the occurrence of liver cancer in Chinese hepatitis B patients, revealing the safety and benefits of interferon application in specific populations. The other explores the immune modulation effects of tenofovir alafenamide (TAF) treatment and predictive indicators of efficacy. "Hepatology Digest" hereby reports on these findings.

AASLD Interview | Professor Wai-Kay Seto’s Team: Presentation of Five Achievements in Predicting Clinical Cure of Hepatitis B and Post-operative Recurrence of Liver Cancer, and Commentary on Liver Disease Research Trends

By Mourabit Halima 2023.12.20

The 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2023) has just concluded in Boston, USA. The team led by Professor Wai-Kay Seto from the University of Hong Kong focused on five research outcomes in the areas of mother-to-child transmission blockage and clinical cure of Hepatitis B, clearance of Hepatitis C, post-operative recurrence of liver cancer, and post-liver transplant management. These outcomes were presented at the meeting, with two of them being shared in the form of oral presentations. Professor Seto's team has been committed to the clinical management and scientific research of chronic liver diseases, achieving fruitful results. Hepatology Digest invited the team's principal researchers to interpret the findings and comment on the trends in liver disease research and share their experiences at the conference. The interview video is shared below.

Professor Lili Liu and Associate Researcher Xuejing Zou’s Team: Targeting Macrophages May Offer New Treatment Strategies for IInhibiting MASH Progres

By Peter W. PENG 2023.12.20

The AASLD 2023 Annual Meeting, hosted by the American Association for the Study of Liver Diseases, recently concluded in Boston, USA. A team led by Professor Lili Liu and Associate Researcher Xuejing Zou from Southern Medical University's Nanfang Hospital in China, including Physician Ziyong Zhang, presented their research in the field of Metabolism-Associated Steatohepatitis (MASH) during the conference's oral presentations (Oral 38). Their study suggests that targeting macrophages may offer a new strategy to inhibit the progression of MASH to liver fibrosis. Dr. Ziyong Zhang was invited to introduce their research at the conference and share his experiences and insights.

Dr. Ming Zhao: Key Clinical Research in Hepatocellular Carcinoma｜Highlights from APPLE 2023

By Lynn 2023.10.23

From July 6th to 8th, 2023, the 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023) was held in Seoul, South Korea. Hepatocellular carcinoma (HCC) experts from around the world gathered to rekindle academic discussions on HCC's basics, clinical aspects, research, and technology offline. The conference featured the latest research results from over a thousand scholars representing more than 50 countries. In this publication, Dr. Ming Zhao from Sun Yat-sen University Cancer Center, China, offers insightful interpretations of the significant clinical research emerging from APPLE 2023 for the benefit of our readers.

IMbrave050 trial results: Atezolizumab combined with bevacizumab can significantly improve RFS in patients with HCC at high risk of recurrence

By Peng Geng 2023.10.13

Recent findings from the phase III IMbrave050 trial presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting have unveiled a significant advancement in the treatment of hepatocellular carcinoma (HCC). The trial investigated the impact of adjuvant therapy with atezolizumab in combination with bevacizumab on recurrence-free survival (RFS) in HCC patients at high risk of recurrence following curative resection or ablation. The study's principal investigator, Professor Pierce Chow of the National Cancer Centre Singapore, revealed the trial's results, suggesting a potential paradigm shift in the management of high-risk HCC patients.

Dr. Xinwei Wang: The Molecular Landscape and Clinical Significance of Liver Cancer

By Lynn 2023.10.13

Dr. Huichuan Sun: Focusing on the Asia-Pacific Region, Leading the Frontier – Exploring Breakthroughs in the Treatment of Hepatobiliary Tumor

By Lynn 2023.10.13

Dr. Zhaochong Zeng: Enhancing Efficiency and Reducing Burden – Latest Advances in Radiotherapy for Liver Cancer Treatment

By Lynn 2023.10.13

Stereotactic Body Radiotherapy (SBRT), as a novel radiotherapy technique, has achieved encouraging results in the treatment of liver cancer. It not only improves local tumor control but also reduces distant metastases caused by tumors. Additionally, it minimizes radiation therapy-related complications, enhancing the quality of life for patients after treatment. However, how to maximize the role of SBRT in comprehensive liver cancer treatment is a topic worthy of further exploration. At the 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023), Dr. Zhaochong Zeng and his team from Zhongshan Hospital, Fudan University, China, presented two studies selected for oral and poster presentations, focusing on improving the effectiveness of SBRT and reducing radiation therapy-related adverse reactions, which attracted significant attention at the conference. In this article, Dr. Zeng shares insights into these two studies.